Foundation Medicine launches liquid biopsy test - MedCity News
World-leading Genomic Testing Services | Foundation Medicine
FoundationOne Liquid CDx
FoundationOne Liquid CDx | Foundation Medicine
Roche annuncia l'approvazione da parte della FDA di FoundationOne Liquid CDx, un servizio diagnostico su biopsia liquida per pazienti con tumore in stadio avanzato, disponibile anche in Italia - Medici Oggi
fmi-10k_20171231.htm
FoundationOne Liquid CDx | Foundation Medicine
Our portfolio
Foundation Medicine Inks $111.5M Genomic Profiling Contract with VA
FoundationOne Liquid CDx
FoundationOne®Liquid CDx
Roche FMI landing page
Comprehensive genomic profiling in oncology – from vision to reality | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
With its liquid biopsy approval, Foundation Medicine takes on Guardant | Evaluate
Commercial Teams
Comprehensive genomic profiling | Foundation Medicine
Foundation Medicine Liquid Biopsy Gets FDA Okay – ISPE Boston
Foundation Medicine Expands Partnership with Sequanta to Provide both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory Filings
AACR 2019 – Foundation Medicine sets the scene for liquid biopsy approval | Evaluate
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin | PLOS ONE
Multi-gene Testing (NGS) for PIK3CA Mutations
FoundationOne Liquid CDx
FoundationOne Liquid CDx (F1 Liquid CDx) – P190032/S005 | FDA
Foundation Medicine and Takeda Announce Collaboration To Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Takeda's Late-Stage Lung Cancer Portfolio | Business Wire
FoundationOne®Liquid CDx
FOUNDATION MEDICAN FountationOne Liquid CDx Peripheral Whole Blood Cancer Test Manuale di istruzioni
